These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38191112)

  • 1. Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice.
    Nie J; Zhou Y; Ding F; Liu X; Yao X; Xu L; Chang Y; Li Z; Wang Q; Zhan L; Zhu L; Xie K; Li C; Shi Y; Zhao Q; Shan Y
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129259. PubMed ID: 38191112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-Assembled Multiepitope Nanovaccine Provides Long-Lasting Cross-Protection against Influenza Virus.
    Nie J; Wang Q; Li C; Zhou Y; Yao X; Xu L; Chang Y; Ding F; Sun L; Zhan L; Zhu L; Xie K; Wang X; Shi Y; Zhao Q; Shan Y
    Adv Healthc Mater; 2024 Apr; 13(10):e2303531. PubMed ID: 37983728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    St-Louis P; Martin C; Khatri V; Bourgault S; Archambault D
    Vaccine; 2024 Apr; 42(9):2144-2149. PubMed ID: 38461047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
    Calzas C; Mao M; Turpaud M; Viboud Q; Mettier J; Figueroa T; Bessière P; Mangin A; Sedano L; Hervé PL; Volmer R; Ducatez MF; Bourgault S; Archambault D; Le Goffic R; Chevalier C
    Front Immunol; 2021; 12():772550. PubMed ID: 34868036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiolated chitosan encapsulation constituted mucoadhesive nanovaccine confers broad protection against divergent influenza A viruses.
    Ding P; Liu H; Zhu X; Chen Y; Zhou J; Chai S; Wang A; Zhang G
    Carbohydr Polym; 2024 Mar; 328():121689. PubMed ID: 38220319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal Nanovaccine Confers Homo- and Hetero-Subtypic Influenza Protection.
    Qi M; Zhang XE; Sun X; Zhang X; Yao Y; Liu S; Chen Z; Li W; Zhang Z; Chen J; Cui Z
    Small; 2018 Mar; 14(13):e1703207. PubMed ID: 29430819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
    Sia ZR; Chiem K; Huang WC; Seffouh A; Teimouri Dereshgi A; Hogan T; Ortega J; Davidson BA; Martinez-Sobrido L; Lovell JF
    J Virol; 2022 Oct; 96(19):e0100622. PubMed ID: 36106872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes.
    Li R; Chowdhury MY; Kim JH; Kim TH; Pathinayake P; Koo WS; Park ME; Yoon JE; Roh JB; Hong SP; Sung MH; Lee JS; Kim CJ
    Vet Microbiol; 2015 Sep; 179(3-4):250-63. PubMed ID: 26210951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Sequential Immunization Using Salmonella Oral Administration Followed by an Intranasal Boost with Ferritin-Based Nanoparticles Enhanced the Humoral Immune Response against H1N1 Influenza Virus.
    Wang Z; Zhang T; Jia F; Ge C; He Y; Tian Y; Wang W; Yang G; Huang H; Wang J; Shi C; Yang W; Cao X; Zeng Y; Wang N; Qian A; Wang C; Jiang Y
    Microbiol Spectr; 2023 Jun; 11(3):e0010223. PubMed ID: 37154735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
    Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
    Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.
    Ding P; Jin Q; Chen X; Yang S; Guo J; Xing G; Deng R; Wang A; Zhang G
    Int J Nanomedicine; 2019; 14():7533-7548. PubMed ID: 31571862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.